-
Electronic (PDF)
-
Site License
-
Enterprisewide
PDL BioPharma, Inc. (PDLI) - Financial and Strategic SWOT Analysis Review
GlobalData, March 2013, Pages: 34
Summary
PDL BioPharma Inc. (PDL) formerly Protein Design Labs, Inc. is a biotechnology company that carries out the humanization of monoclonal antibodies and the discovers a new generation of targeted treatments for immunologic diseases and cancer. The company focuses on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. It receives royalties for the sales of humanized antibody products marketed today and humanized antibody products launched before final patent expiry of Queen et al. in December 2014.
PDL BioPharma, Inc. Key Recent Developments
Mar 01, 2013: PDL BioPharma Reports Revenue Of $375m In 2012
Dec 03, 2012: PDL BioPharma's CFO Bruce Tomlinson To Resign
Nov 05, 2012: PDL BioPharma Reports Revenue Of $85.2m In Q3 2012
Aug 02, 2012: PDL BioPharma Reports Revenue Of $125.9m In Q2 2012
May 03, 2012: PDL BioPharma Reports Revenue Of $77.3m In Q1 2012
This comprehensive SWOT profile of PDL BioPharma, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
List of Tables
List of Figures
Section 1 - About the Company
PDL BioPharma, Inc. - Key Facts
PDL BioPharma, Inc. - Key Employees
PDL BioPharma, Inc. - Key Employee Biographies
PDL BioPharma, Inc. - Major Products and Services
PDL BioPharma, Inc. - History
PDL BioPharma, Inc. - Company Statement
PDL BioPharma, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
PDL BioPharma, Inc. - Business Description
PDL BioPharma, Inc. - SWOT Analysis
SWOT Analysis - Overview
PDL BioPharma, Inc. - Strengths
Strength - Technological Capabilities
Strength - Intellectual Properties
Strength - Licensing Agreements
PDL BioPharma, Inc. - Weaknesses
Weakness - Patent Challenges
PDL BioPharma, Inc. - Opportunities
Opportunity - Growth Prospects: Oncology
Opportunity - Rising Healthcare Expenditure in the US
Opportunity - Demographic Trends
PDL BioPharma, Inc. - Threats
Threat - Uncertain R&D Outcomes
Threat - Industry Regulations
Threat - Rapid Technological Advancements
PDL BioPharma, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
PDL BioPharma, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
PDL BioPharma, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
PDL BioPharma, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
PDL BioPharma, Inc., Recent Developments
Mar 01, 2013: PDL BioPharma Reports Revenue Of $375m In 2012
Dec 03, 2012: PDL BioPharma's CFO Bruce Tomlinson To Resign
Nov 05, 2012: PDL BioPharma Reports Revenue Of $85.2m In Q3 2012
Aug 02, 2012: PDL BioPharma Reports Revenue Of $125.9m In Q2 2012
May 03, 2012: PDL BioPharma Reports Revenue Of $77.3m In Q1 2012
Apr 26, 2012: PDL BioPharma Appoints Bruce Tomlinson As CFO
Feb 23, 2012: PDL BioPharma Reports Revenue Of $72.8m In Q4 2011
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer
List of Tables
PDL BioPharma, Inc., Key Facts
PDL BioPharma, Inc., Key Employees
PDL BioPharma, Inc., Key Employee Biographies
PDL BioPharma, Inc., Major Products and Services
PDL BioPharma, Inc., History
PDL BioPharma, Inc., Subsidiaries
PDL BioPharma, Inc., Key Competitors
PDL BioPharma, Inc., Ratios based on current share price
PDL BioPharma, Inc., Annual Ratios
PDL BioPharma, Inc., Interim Ratios
PDL BioPharma, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
PDL BioPharma, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
PDL BioPharma, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
PDL BioPharma, Inc., Performance Chart (2008 - 2012)
PDL BioPharma, Inc., Ratio Charts
PDL BioPharma, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
PDL BioPharma, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013
Genmab A/S
Dyax Corp.
Gilead Sciences, Inc.
Seattle Genetics, Inc.
Genentech, Inc.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
